Throughout 2016, Next Phase has brought you updates and advice on early stage life science fundraising. This week, we'd like to take a look back at the highlights of the year, from some hard data on drug development funding to tips on marketing and pitching your company. We hope you enjoy this roundup of our top 10 articles of the year. See you in 2017.
The 11th Redefining Early Stage Investments (RESI) Conference will be joining the JPM fray for our largest event yet on January 10th in San Francisco. We're excited to announce the early stage life science companies that will be participating in the RESI Innovation Challenge.
The 30 participating companies have been hand-selected by LSN's scientific review committee based on the innovative nature of their core technology and how well-positioned each is to capitalize on their respective market opportunities.
Large technology companies have been expanding their footprint in the healthcare sector through venture investment and partnerships into early stage healthcare companies. Often seeking technology with a significant software component, many of these groups have helped to fuel the massive growth that has been seen in the digital health space in the past few years. From patient monitoring devices to mobile 3D imaging devices the lines between pure tech and healthcare are slowly beginning to blur as healthcare providers continually look to improve care while lowering costs.
Moderated by Michael Greeley, General Partner, Flare Capital Partners, the panelists are:
Iana Dimkova, Senior Associate, Healthcare, GE Ventures
Lucian Iancovici, FACHE, Head of Qualcomm Life Fund, Qualcomm Ventures
Rich Wilmot, Head of Corporate Venturing, Philips
Ying Tam, Head, Digital Health Cluster, Venture Services, MaRS
Life Science Investor Mandates
